Diabetic Macular Edema Treatment Market By Treatment (By Drugs, By Surgery, Pipeline Analysis) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

World Health Organization 2014 survey states that globally around 422 million people suffer with diabetes and approximately 2.6 % of the global blindness is due to diabetic retinopathy. The American Academy of Ophthalmology has stated that the incidence rate of diabetic macular edema in a span of 10 years to be 20 % in younger patients and 40 % in older patients. Currently combined therapy of photocoagulation laser therapy and Anti-VEGF drugs are employed to achieve improved vision and avoid blindness. The drugs in phase III clinical trials such as conbercept, pemofibrate, ranibizumab and aflibercept intravitreal injection are tested for better drug efficacy.

Therapy segment for the diabetic macular edema treatment market majorly comprises drugs and surgery. The drugs are further sub segmented as Anti-VEGF, Corticosteroids and other drugs (Triamcinolone Acetonide and Bevacizumab). Anti-VEGF treatment adopted is Ranibizumab and Aflibercept. Corticosteroids includes dexamethasone and Fluocinolone Acetonide. The surgery segment comprises of photocoagulation laser therapy and intravitreal implants. In order to understand the current trend existing in the market the data forecast and market estimation for treatment segment is given in the scope of the report.

Brief description of the treatment regimen adopted across 5 major geographical region is covered in the geography segment which is as follows:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimation along with the data forecasting is given for the geographical regions and the cross country sectional is given for the treatment segment.

Competitive landscape is an assessment tool highlights the performance of the fundamental players currently engaged in the diabetic macular edema treatment market. The parameters employed are geographical presence, product portfolio and inception. Company profiles gives a brief update regarding the latest technological advancement in the photocoagulation laser therapy market and effective collaboration among niche players. The fundamental players in the diabetic macular edema treatment market are Allergan, Inc., Quantel-Medical, Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., IRIDEX Corporation, LUMENIS, Novartis AG, and Regeneron Pharmaceuticals, Inc.

Diabetic Macular Edema Treatment Market

Choose License Type
Published Date:  Jan 2018
Category:  Medical Devices
Report ID:   58932
Report Format:   PDF
Pages:   120
Rating:    4.2 (34)
Connect With Us
+1-408-641-3282
24/7 Research Support